Covid 19 Research using Clinical Trials (Home Page)
Report for D012213: Rheumatic Fever NIH
(Synonyms: Rheumatic Fever)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
|
Name (Synonyms) |
Correlation |
drug155 | COVID-19 diagnostic test Wiki | 1.00 |
Correlated MeSH Terms (3)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2
called covid-19 has become a global challenge. In France, while the first cases were reported
in January, more than 20 000 cases were confirmed at end of March. Early estimations from
epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are
admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism,
auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe
covid-19 (i.e ICU) due to the specific therapeutic management of their illness
(corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for
this particular population in France.
This retrospective multicentre observational study aims to evaluate the frequency of severe
forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients
with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare
diseases.
NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19
Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19
Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
HPO Nodes